Mediolanum Farmaceutici<\/strong>, a family pharmaceutical company headed by the founder\u00a0Rinaldo Del Bono<\/strong>, is in talks with possible new financial partners who can support the new phase of development of the company. He writes it The sun 24 hours<\/em>, But Ardian may not be the only fund studying the dossier. Also because Mediolanum Farmaceutici knows the world of private equity well, having been a shareholder, albeit with a small minority, of BFF Farmafactoring<\/strong> before it went public and that is when control of the bank had first been in the hands of Apax Partners <\/strong>and then say Centerbridge<\/strong> (see other article by BeBeez<\/em><\/a>). While in the sector it is very present cvc extension<\/strong> which owns both Recordati (see other article by\u00a0BeBeez<\/em><\/a>) and Doc Generici (see other article by\u00a0BeBeez<\/em><\/a>), which it took over from Charterhouse<\/strong> in 2016.<\/p>\n Founded in Milan in 1972 and led by the managing director Alessandro DelBono,<\/strong> Mediolanum Farmaceutici closed 2017 with approximately 200 million euros of consolidated revenues from 176.2 million in 2016, when it had recorded an ebitda of 49.4 million and a net profit of 11.3 million, in the presence of net liquidity ( positive net financial position) of 27.5 million (see here the analysis of Leanus<\/a>, after registering for free).<\/p>\n Last year Mediolanum Farmaceutici acquired the Italian branch of the Belgian company\u00a0Therabel Gienne Pharma<\/strong>, has signed the partnership between\u00a0Levante pharma\u00a0<\/strong>(a company of the Mediolanum pharmaceutical Group dedicated to breathing) e\u00a0Teva Pharmaceutical,<\/strong> has\u00a0<\/strong>relaunched theGentile Institute<\/strong>, totally dedicated to oncology. Also in the oncological field, in 2017 it was born\u00a0Mediolanum Biosciences<\/strong>\u00a0with the creation of two new business units in France and Germany dedicated to the promotion of a new anticancer therapy.<\/p>","protected":false},"excerpt":{"rendered":" Mediolanum Farmaceutici in trattative con i fondi. Ardian in pole Milano Finanza – ottobre 02, 2018 Mediolanum Farmaceutici, azienda farmaceutica familiare che fa capo\u00a0al fondatore\u00a0Rinaldo Del Bono, \u00e8 in trattative con possibili nuovi partner finanziari che possano supportare la nuova fase di sviluppo della societ\u00e0. Lo scrive Il Sole 24 Ore, precisando che sul mercato …<\/p>","protected":false},"author":4,"featured_media":38483,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[53],"class_list":["post-38481","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-fusioniacquisizioni"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/38481","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=38481"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/38481\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/38483"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=38481"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=38481"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=38481"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"\"](\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2018\/10\/Ardian-Mediolanum.png\")
<\/a>specifying that the name of is circulating on the market Ardian<\/strong> as the most likely candidate for the operation.<\/p>\n